R&D channel feed – Endpoints News

R&D channel feed

AstraZeneca’s triplet with Imfinzi, treme and chemo works on a key endpoint for frontline lung cancer

6 years ago

Mixed early data on Agios' AG-270 suggest combo therapy could be way forward

6 years ago

A GSK-led consortium looks to break ground with a new class of antibiotic, pushing into a pivotal

6 years ago

AbbVie doubles down on cystic fibrosis R&D, adding a new drug to the pipeline as Vertex seals its domination of the field with Trikafta OK

6 years ago

Gilead execs flag trial failures for Sjögren’s and lupus drugs — while swapping out a favorite HIV program of top analyst

6 years ago

Amgen commits to low-cost Repatha; AZTherapies bags Smith Therapeutics' CAR-Treg tech for neuroinflammation

6 years ago

Syros pushes for a turnaround with new PhII AML results, but investors are unimpressed

6 years ago

Impressing analysts with a big Q3, AstraZeneca whisks away the losers in the pipeline

6 years ago

Vertex finally makes NICE with England's NHS on CF therapies, but runs into hiccup with preclinical kidney drug data

6 years ago

Public funds help late-stage development of about 25% of new drugs, study finds

6 years ago

From $0 to $12B in an instant. Here's why biopharma loves risky Alzheimer's studies

6 years ago

Allievex launches with Pappas cash and rare disease drug from BioMarin

6 years ago

Go big or go home: NIH, Bill and Melinda Gates Foundation join forces to make gene therapies affordable

6 years ago

Acorda's Ron Cohen brings the ax back out as new drug sales only trickle in while cash cow is led to the slaughter

6 years ago

RAPT Therapeutics returns to Wall Street to revive IPO bid

6 years ago

As shares suffer from a lingering slump, a bruised Alkermes slashes 160 jobs in R&D restructuring

6 years ago

Jean-Paul Clozel downplays recruitment delays holding up PhIII for Fabry disease

6 years ago

Novartis hands off $80M in cash to partner up with a top biotech player in the fibrosis sector

6 years ago

Is there a recipe for M&A success? The best and worst buyout deals in the past decade offer some keys to success — and failure

6 years ago

Provention Bio's J&J-licensed Crohn's drug stumbles in mid-stage study

6 years ago

David Liu unveils newest advancement in CRISPR tech: Prime editing

6 years ago

A new company enters the Tecfidera fight, offering to kill two birds

6 years ago

Bristol-Myers makes Opdivo pitch for frontline lung cancer with open label PhIII study

6 years ago

In a stunning turnaround, Biogen says that aducanumab does work for Alzheimer's — but data mining incites controversy and questions

6 years ago

First page Previous page 226 227 228229230 231 232 Next page Last page